SCHEMBL4305909

SCHEMBL4305909

C=CC(=O)N[C@@H](CS)C(=O)O

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.55
MAPT P10636 1/20 0.55
THRB P10828 1/20 0.55
ALOX15 P16050 1/20 0.55
NFKB1 P19838 1/20 0.55
PTGS2 P35354 1/20 0.55
THPO P40225 1/20 0.55
RECQL P46063 1/20 0.55
BLM P54132 1/20 0.55
SMN1; SMN2 Q16637 1/20 0.55
ACE P12821 1/20 0.50
FOLH1 Q04609 1/20 0.47
TSHR P16473 2/20 0.45
CA1 P00915 3/20 0.38
CA2 P00918 3/20 0.38
ALDH1A1 P00352 1/20 0.38
MAPK1 P28482 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
FNTA P49354 2/20 0.36
FNTB P49356 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3054458 1.00 KDM4E (0.55) KDM4EMAPTTHRBALOX15NFKB1
SCHEMBL29587402 0.84 TSHR (0.42) KDM4EMAPTTHRBALOX15NFKB1
SCHEMBL8379982 0.82 TSHR (0.43) KDM4EMAPTTHRBALOX15NFKB1
SCHEMBL8379983 0.82 TSHR (0.43) KDM4EMAPTTHRBALOX15NFKB1
SCHEMBL27619146 0.81 KDM4E (0.57) KDM4EMAPTTHRBALOX15NFKB1
SCHEMBL6513640 0.81 TGFBR1 (0.52) TSHRCA1CA2ALDH1A1MAPK1
SCHEMBL6513633 0.81 TGFBR1 (0.52) TSHRCA1CA2ALDH1A1MAPK1
SCHEMBL29285204 0.80 KDM4E (0.57) KDM4EMAPTTHRBALOX15NFKB1
SCHEMBL4289576 0.80 KDM4E (0.42) KDM4EMAPTTHRBALOX15NFKB1
SCHEMBL29285206 0.80 KDM4E (0.57) KDM4EMAPTTHRBALOX15NFKB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024051132-A1 COLCHICINE HYDROGEL MICRONEEDLE AND PREPARATION METHOD THEREFOR 安徽中医药大学 2024-03-14 WO claimed
US-12558432-B2 Biocompatible polymeric drug carriers for delivering active agents CIS BIOPHARMA AG (CH) 2026-02-24 US disclosed
US-12265082-B2 Detecting microbial infection in wounds SYNOVO GMBH (DE) 2025-04-01 US disclosed
WO-2024205472-A1 COMPOSITION FOR USE IN PREVENTION AND/OR TREATMENT OF HUMAN TRANSTHYRETIN AMYLOIDOSIS OLOFSSON ANDERS (SE) 2024-10-03 WO disclosed
EP-4406984-A1 DUROPLASTIC CAST MATERIAL, MOLDED BODY PRODUCED THEREFROM AND METHOD FOR PRODUCING A MOLDED BODY OF THIS TYPE Schock GmbH (DE) 2024-07-31 EP disclosed
US-20240027454-A1 DETECTING MICROBIAL INFECTION IN WOUNDS SYNOVO GMBH (DE) 2024-01-25 US disclosed
US-11740241-B2 Construct including an anchor, an enzyme recognition site and an indicator region for detecting microbial infection in wounds SYNOVO GMBH (DE) 2023-08-29 US disclosed
US-20220409737-A1 BIOCOMPATIBLE POLYMERIC DRUG CARRIERS FOR DELIVERING ACTIVE AGENTS CIS BIOPHARMA AG (CH) 2022-12-29 US disclosed
CN-114245881-A Photosensitive resin composition 日产化学株式会社 2022-03-25 CN disclosed
CN-114174351-A Resin composition 日产化学株式会社 2022-03-11 CN disclosed
WO-2012123275-A1 THERMO-RESPONSIVE HYDROGEL COMPOSITIONS CHEMISCHES INSTITUT SCHAEFER (CH) 2012-09-20 WO disclosed
US-20120231072-A1 THERMO-RESPONSIVE HYDROGEL COMPOSITIONS CHEMISCHES INSTITUT SCHAEFER AG (CH) 2012-09-13 US disclosed
US-7485460-B2 Enhanced growth of adult stem cells with Dkk-1 TULANE UNIVERSITY HEALTH SCIENCES CENTER (US) 2009-02-03 US disclosed
US-20080085281-A1 Using modulators of Dickkopf homolog 1 (DKK-1) activity as tool in treatment and prevention of osteolytic lesion; wnt signaling antagonist; antitumor agents THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND (US) 2008-04-10 US disclosed
EP-1508042-A4 BIOCHIPS WITH SURFACES COATED WITH POLYSACCHARIDE BASED HYDROGELS BIO RAD LABORATORIES (US) 2008-04-02 EP disclosed
US-20050084494-A1 Inhibitors of Dkk-1 ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND, THE 2005-04-21 US disclosed
EP-1508042-A2 BIOCHIPS WITH SURFACES COATED WITH POLYSACCHARIDE BASED HYDROGELS Ciphergen Biosystems, Inc. (US) 2005-02-23 EP disclosed
US-20040235166-A1 Enhanced growth of adult stem cells TULANE UNIVERSITY HEALTH SCIENCES CENTER 2004-11-25 US disclosed
US-20030218130-A1 Biochips with surfaces coated with polysaccharide-based hydrogels CIPHERGEN BIOSYSTEMS, INC. 2003-11-27 US disclosed
WO-2003093785-A2 BIOCHIPS WITH SURFACES COATED WITH POLYSACCHARIDE BASED HYDROGELS CIPHERGEN BIOSYSTEMS, INC. (US) 2003-11-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12558432-B2 Biocompatible polymeric drug carriers for delivering active agents MSR1, CD47, SLC43A1 KDM4E 3537/4885MAPT 4632/4885THRB 1407/4885
US-20220409737-A1 BIOCOMPATIBLE POLYMERIC DRUG CARRIERS FOR DELIVERING ACTIVE AGENTS CD47, DNPEP, MSR1 KDM4E 2133/4885MAPT 3895/4885THRB 3282/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.